Greffe de cellules souches hématopoïétiques haplo-identiques avec cyclophosphamide en post-greffe : comment choisir le meilleur donneur en 2019 ? Recommandations de la Société francophone de greffe de mœlle et de thérapie cellulaire (SFGM-TC)

Dubois, V.; Amokrane, K.; Beguin, Yves; Bruno, B.; Chevallier, P.; Delbos, F.; Devillier, R.; Giannoli, C.; Guidicelli, G.; Harif, M.; Loiseau, P.; Rouzaire, P.-O.; Varlet, P.; Yakoub-Agha, I.; Nguyen, S.

doi:10.1016/j.bulcan.2019.07.011

Article (Scientific journals)

Greffe de cellules souches hématopoïétiques haplo-identiques avec cyclophosphamide en post-greffe : comment choisir le meilleur donneur en 2019 ? Recommandations de la Société francophone de greffe de mœlle et de thérapie cellulaire (SFGM-TC)

Dubois, V.; Amokrane, K.; Beguin, Yves et al.

2020 • In Bulletin du Cancer, 107 (Suppl. 1), p. 72-84

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/244746

DOI
10.1016/j.bulcan.2019.07.011

PubMed
31586527

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

433 Haplo SFGM 2019-Bull.Cancer 2020.pdf

Publisher postprint (1.22 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Donor choice; DSA; Haploidentical transplantation

Abstract :

[en] Haploidentical hematopoietic stem cell transplantation has been growing steadily since 2012. The SFGM-TC has twice published guidelines concerning T-cell repleted haploidentical grafts with high dose cyclophosphamide post-transplantation. The 2013 workshop recommended using the non-myeloablative Baltimore protocol with bone marrow and developed prospective protocols to evaluate these transplantations. The 2015 workshop reported improved results of reduced conditioning regimens in Hodgkin's lymphoma and intensive conditioning in myeloid hemopathies, and a similar outcome with 10/10 HLA matched donor with the same disease-risk score thus raising the question of the qualifier “alternative” for haploidentical transplants. The current work concerns the criteria for selecting the donor. The main criterion remains the absence of anti-HLA antibodies directed against the donor present in the recipient sera (DSA – Donor Specific Antibodies). In case of DSA and in the absence of an alternative donor, desensitization protocols exist. The other criteria are impossible to prioritize: age, sex, CMV, and blood type. The degree of relatedness and the number of HLA incompatibilities do not seem to be a criterion of choice. The ‘ideal’ donor would be a young man, CMV-matched, without major ABO incompatibility with a marrow transplant. There is insufficient data for the KIR-ligand and NIMA/NIPA mismatch. Peripheral stem cell grafts appear to yield more acute GVHD than bone marrow grafts after intensive conditioning, but with comparable survival rates. Based on the literature review, the comparison of haploidentical with unrelated donors encourages inclusion in existing national protocols randomizing these different donors. © 2019

Disciplines :

Hematology

Author, co-author :

Dubois, V.; EFS Auvergne Rhône Alpes, Laboratoire HLA, 111, rue Elisée-Reclus, Décines, 69150, France

Amokrane, K.; Hôpital Saint-Louis, laboratoire d'immunologie et histocompatibilité, 01, avenue Claude-Vellefaux, Paris, 75010, France

Beguin, Yves ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie

Bruno, B.; CHU de Lille, hématologie pédiatrique, Lille, 59000, France

Chevallier, P.; CHU de l'Hôtel-Dieu, Service d'hématologie clinique, place A. Ricordeau, Nantes cedex, 44093, France

Delbos, F.; EFS centre Pays de la Loire, Laboratoire HLA, 34, rue Jean-Monnet, Nantes, 44000, France

Devillier, R.; Aix-Marseille Université, Institut Paoli-Calmettes, CNRS, CRCM, Inserm, Marseille, 13000, France

Giannoli, C.; EFS Auvergne Rhône Alpes, Laboratoire HLA, 111, rue Elisée-Reclus, Décines, 69150, France

Guidicelli, G.; CHU de Pellegrin, Laboratoire immunologie et immunogénétique, place Amélie-Raba-Leon, Bordeaux cedex, 33076, France

Harif, M.; CHU d'Ibn-Rochd, Service d'hématologie et oncologie pédiatrique, 6, rue Larjoun, quartier des Hôpitaux, Casablanca, 20360, Morocco

More authors (5 more)

Language :

French

Title :

Alternative titles :

[en] Haploidentical hematopoietic stem cell transplant: How to choose the best donor? Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Publication date :

2020

Journal title :

Bulletin du Cancer

ISSN :

0007-4551

eISSN :

1769-6917

Publisher :

John Libbey Eurotext

Volume :

107

Issue :

Suppl. 1

Pages :

72-84

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 13 February 2020

Statistics

Number of views

1059 (8 by ULiège)

Number of downloads

1449 (24 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Tipton, R., Yakoub-Agha, I., How we harmonize HSCT clinical practices among the SFGM-TC centers. Bull Cancer (Paris) 103:11S (2016), S193–S197.
Blaise, D., Nguyen, S., Bay, J.-O., Chevallier, P., Contentin, N., Dhédin, N., et al. Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (Part 1). Pathol Biol (Paris) 62:4 (2014), 180–184.
Nguyen, S., Blaise, D., Bay, J.-O., Chevallier, P., Contentin, N., Dhédin, N., et al. Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (part 2). Pathol Biol (Paris) 62:4 (2014), 185–189.
Nguyen, S., Chalandon, Y., Lemarie, C., Simon, S., Masson, D., Dhedin, N., et al. Haploidentical hematopoietic stem cell transplantation: guidelines from the francophone society of marrow transplantation and cellular therapy (SFGM-TC). Bull Cancer (Paris) 103:11S (2016), S229–S242.
Ciurea, S.O., Thall, P.F., Milton, D.R., Barnes, T.H., Kongtim, P., Carmazzi, Y., et al. Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 21:8 (2015), 1392–1398.
Kanter Berga, J., Sancho Calabuig, A., Gavela Martinez, E., Puig Alcaraz, N., Avila Bernabeu, A., Crespo Albiach, J., et al. Desensitization protocol in recipients of deceased kidney donor with donor-specific antibody-low titers. Transplant Proc 48:9 (2016), 2880–2883.
Chang, Y.-J., Zhao, X.-Y., Xu, L.-P., Zhang, X.-H., Wang, Y., Han, W., et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol Oncol, 8, 2015, 84.
Ciurea, S.O., de Lima, M., Cano, P., Korbling, M., Giralt, S., Shpall, E.J., et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 88:8 (2009), 1019–1024.
Yoshihara, S., Maruya, E., Taniguchi, K., Kaida, K., Kato, R., Inoue, T., et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 47:4 (2012), 508–515.
Ciurea, S.O., Cao, K., Fernandez-Vina, M., Kongtim, P., Malki, M.A., Fuchs, E., et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of Donor-Specific Anti-HLA Antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant 53:5 (2018), 521–534.
Yamamoto, H., Uchida, N., Matsuno, N., Ota, H., Kageyama, K., Wada, S., et al. Anti-HLA antibodies other than against HLA-A, -B, -DRB1 adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies. Biol Blood Marrow Transplant 20:10 (2014), 1634–1640.
Yamashita, T., Ikegame, K., Kojima, H., Tanaka, H., Kaida, K., Inoue, T., et al. Effective desensitization of donor-specific HLA antibodies using platelet transfusion bearing targeted HLA in a case of HLA-mismatched allogeneic stem cell transplantation. Bone Marrow Transplant 52:5 (2017), 794–796.
Kongtim, P., Cao, K., Ciurea, S.O., Donor Specific Anti-HLA Antibody and risk of graft failure in haploidentical stem cell transplantation. Adv Hematol, 2016, 2016, 4025073.
Jordan, S.C., Choi, J., Kahwaji, J., Vo, A., Progress in desensitization of the highly HLA sensitized patient. Transplant Proc 48:3 (2016), 802–805.
Vo, A.A., Choi, J., Cisneros, K., Reinsmoen, N., Haas, M., Ge, S., et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation 98:3 (2014), 312–319.
Kasamon, Y.L., Luznik, L., Leffell, M.S., Kowalski, J., Tsai, H.-L., Bolaños-Meade, J., et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 16:4 (2010), 482–489.
Solomon, S.R., Aubrey, M.T., Zhang, X., Piluso, A., Freed, B.M., Brown, S., et al. Selecting the best donor for haploidentical transplant: impact of HLA. Killer cell immunoglobulin-like receptor genotyping, and other clinical variables. Biol Blood Marrow Transplant 24:4 (2018), 789–798.
McCurdy, S.R., Zhang, M.-J., St Martin, A., Al Malki, M.M., Bashey, A., Gaballa, S., et al. Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Adv 2:3 (2018), 299–307.
Ciurea, S.O., Shah, M.V., Saliba, R.M., Gaballa, S., Kongtim, P., Rondon, G., et al. Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 24:6 (2018), 1232–1236.
Canaani, J., Savani, B.N., Labopin, M., Huang, X.-J., Ciceri, F., Arcese, W., et al. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. Am J Hematol 93:2 (2018), 246–253.
Wang, Y., Chang, Y.-J., Xu, L.-P., Liu, K.-Y., Liu, D.-H., Zhang, X.-H., et al. Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood 124:6 (2014), 843–850.
Chang, Y.-J., Luznik, L., Fuchs, E.J., Huang, X.-J., How do we choose the best donor for T-cell-replete. HLA-haploidentical transplantation?. J Hematol Oncol, 9, 2016, 35.
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P.V., Mar, B.G., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:26 (2014), 2488–2498.
Cesaro, S., Crocchiolo, R., Tridello, G., Knelange, N., Van Lint, M.T., Koc, Y., et al. Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. Bone Marrow Transplant 53:4 (2018), 422–430.
Raiola, A.M., Risitano, A., Sacchi, N., Giannoni, L., Signori, A., Aquino, S., et al. Impact of HLA disparity in haploidentical bone marrow transplantation followed by high-dose cyclophosphamide. Biol Blood Marrow Transplant 24:1 (2018), 119–126.
Lorentino, F., Labopin, M., Fleischhauer, K., Ciceri, F., Mueller, C.R., Ruggeri, A., et al. The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. Blood Adv 1:11 (2017), 669–680.
Robinson, T.M., Fuchs, E.J., Zhang, M.-J., St Martin, A., Labopin, M., Keesler, D.A., et al. Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. Blood Adv 2:11 (2018), 1180–1186.
Huo, M.-R., Pei, X.-Y., Li, D., Chang, Y.-J., Xu, L.-P., Zhang, X.-H., et al. Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. Bone Marrow Transplant 53:5 (2018), 600–608.
McCurdy, S.R., Muth, S.T., Tsai, H.-L., Symons, H.J., Huff, C.A., Matsui, W.H., et al. Early fever after haploidentical bone marrow transplantation correlates with class II HLA-mismatching and myeloablation but not outcomes. Biol Blood Marrow Transplant 24:10 (2018), 2056–2064.
Nguyen, S., Béziat, V., Roos-Weil, D., Vieillard, V., Role of natural killer cells in hematopoietic stem cell transplantation: myth or reality?. J Innate Immun 3:4 (2011), 383–394.
Ciurea, S.O., Al Malki, M.M., Kongtim, P., Fuchs, E.J., Luznik, L., Huang, X.-J., et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant, 2019, 10.1038/s41409-019-0499-z.
Wanquet, A., Bramanti, S., Harbi, S., Fürst, S., Legrand, F., Faucher, C., et al. Killer cell immunoglobulin-like receptor-ligand mismatch in donor versus recipient direction provides better graft-versus-tumor effect in patients with hematologic malignancies undergoing allogeneic T cell-replete haploidentical transplantation followed by post-transplant cyclophosphamide. Biol Blood Marrow Transplant 24:3 (2018), 549–554.
Symons, H.J., Leffell, M.S., Rossiter, N.D., Zahurak, M., Jones, R.J., Fuchs, E.J., Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative. HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 16:4 (2010), 533–542.
Bastos-Oreiro, M., Anguita, J., Martínez-Laperche, C., Fernández, L., Buces, E., Navarro, A., et al. Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation. Eur J Haematol 96:5 (2016), 483–491.
Russo, A., Oliveira, G., Berglund, S., Greco, R., Gambacorta, V., Cieri, N., et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood 131:2 (2018), 247–262.
Shimoni, A., Labopin, M., Lorentino, F., Van Lint, M.T., Koc, Y., Gülbas, Z., et al. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia 33:1 (2019), 230–239.
Torío, A., Pascual, M.J., Vidales, I., Ortiz, M., Caballero, A., Heiniger, A.I., Donor selection based on Killer Cell Immunoglobulin-Like Receptor (KIR) genotype may improve outcome after T-Cell-Replete haploidentical transplantation. Transplant Proc 50:2 (2018), 679–682.
Wang, Y., Zhao, X.-Y., Xu, L.-P., Zhang, X.-H., Han, W., Chen, H., et al. Lower incidence of acute GVHD is associated with the rapid recovery of CD4 + CD25 + CD45RA + regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: a retrospective (development) and prospective (validation) cohort-based study. Oncoimmunology, 5(12), 2016, e1242546.
Castagna, L., Crocchiolo, R., Furst, S., Bramanti, S., El Cheikh, J., Sarina, B., et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 20:5 (2014), 724–729.
Devillier, R., Granata, A., Fürst, S., Harbi, S., Faucher, C., Weiller, P.-J., et al. Low incidence of chronic GVHD after HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in older patients. Br J Haematol 176:1 (2017), 132–135.
Mussetti, A., De Philippis, C., Carniti, C., Bastos-Oreiro, M., Gayoso, J., Cieri, N., et al. CD3 + graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. Bone Marrow Transplant 53:12 (2018), 1522–1531.
Bashey, A., Zhang, M.-J., McCurdy, S.R., St Martin, A., Argall, T., Anasetti, C., et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-Cell-Replete haploidentical donor transplantation using post-transplant cyclophosphamide. J Clin Oncol 35:26 (2017), 3002–3009.
Ruggeri, A., Labopin, M., Bacigalupo, A., Gülbas, Z., Koc, Y., Blaise, D., et al. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer 124:7 (2018), 1428–1437.
Brunstein, C.G., Fuchs, E.J., Carter, S.L., Karanes, C., Costa, L.J., Wu, J., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 118:2 (2011), 282–288.
Esteves, I., Santos, F.P.S., Ribeiro, A.A.F., Kondo, A.T., Fernandes, J.F., Kerbauy, F.R., et al. Survival, toxicity and length of stay after haploidentical or cord blood transplantation in a Latin American center: a cross-sectional, comparative study. Blood Cancer J, 7(5), 2017, e563.
Ruggeri, A., Labopin, M., Sanz, G., Piemontese, S., Arcese, W., Bacigalupo, A., et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia 29:9 (2015), 1891–1900.
El-Cheikh, J., Crocchiolo, R., Furst, S., Bramanti, S., Sarina, B., Granata, A., et al. Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies. Cancer 121:11 (2015), 1809–1816.
Kekre, N., Antin, J.H., Cord blood versus haploidentical stem cell transplantation for hematological malignancies. Semin Hematol 53:2 (2016), 98–102.
Ciurea, S.O., Zhang, M.-J., Bacigalupo, A.A., Bashey, A., Appelbaum, F.R., Aljitawi, O.S., et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 126:8 (2015), 1033–1040.
Salvatore, D., Labopin, M., Ruggeri, A., Battipaglia, G., Ghavamzadeh, A., Ciceri, F., et al. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the acute leukemia working party of the European Society for blood and marrow transplantation. Haematologica 103:8 (2018), 1317–1328.
Solomon, S.R., Sizemore, C.A., Sanacore, M., Zhang, X., Brown, S., Holland, H.K., et al. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant 21:7 (2015), 1299–1307.
Raiola, A.M., Dominietto, A., di Grazia, C., Lamparelli, T., Gualandi, F., Ibatici, A., et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 20:10 (2014), 1573–1579.
Blaise, D., Fürst, S., Crocchiolo, R., El-Cheikh, J., Granata, A., Harbi, S., et al. Haploidentical T Cell-Replete transplantation with post-transplantation cyclophosphamide for patients in or above the sixth decade of age compared with allogeneic hematopoietic stem cell transplantation from an human leukocyte antigen-matched related or unrelated donor. Biol Blood Marrow Transplant 22:1 (2016), 119–124.
Devillier, R., Legrand, F., Rey, J., Castagna, L., Fürst, S., Granata, A., et al. HLA-Matched sibling versus unrelated versus haploidentical related donor allogeneic hematopoietic stem cell transplantation for patients aged over 60 years with acute myeloid leukemia: a single-center donor comparison. Biol Blood Marrow Transplant 24:7 (2018), 1449–1454.
Pagliardini, T., Harbi, S., Fürst, S., Castagna, L., Legrand, F., Faucher, C., et al. Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients. Bone Marrow Transplant 54:7 (2018), 1067–1076.
How, J., Slade, M., Vu, K., DiPersio, J.F., Westervelt, P., Uy, G.L., et al. T Cell-Replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia. Biol Blood Marrow Transplant 23:4 (2017), 648–653.
Drobyski, W.R., Klein, J., Flomenberg, N., Pietryga, D., Vesole, D.H., Margolis, D.A., et al. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 99:3 (2002), 806–814.
Gaballa, S., Ge, I., El Fakih, R., Brammer, J.E., Kongtim, P., Tomuleasa, C., et al. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122:21 (2016), 3316–3326.
Moiseev, I.S., Pirogova, O.V., Alyanski, A.L., Babenko, E.V., Gindina, T.L., Darskaya, E.I., et al. Risk-adapted GVHD prophylaxis with post-transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations. Eur J Haematol 100:5 (2018), 395–402.
Martínez, C., Gayoso, J., Canals, C., Finel, H., Peggs, K., Dominietto, A., et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for hodgkin lymphoma: a registry study of the lymphoma working party of the European Society for Blood and Marrow Transplantation. J Clin Oncol 35:30 (2017), 3425–3432.
Mariotti, J., Devillier, R., Bramanti, S., Sarina, B., Furst, S., Granata, A., et al. T Cell-Replete haploidentical transplantation with post-transplantation cyclophosphamide for hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with HLA-Identical related donors. Biol Blood Marrow Transplant 24:3 (2018), 627–632.
Michel, G., Galambrun, C., Sirvent, A., Pochon, C., Bruno, B., Jubert, C., et al. Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. Blood 127:26 (2016), 3450–3457.
Bradstock, K.F., Bilmon, I., Kwan, J., Micklethwaite, K., Blyth, E., Deren, S., et al. Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease. Biol Blood Marrow Transplant 21:5 (2015), 941–944.
O'Donnell, P.V., Eapen, M., Horowitz, M.M., Logan, B.R., DiGilio, A., Brunstein, C., et al. Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. Bone Marrow Transplant 51:12 (2016), 1599–1601.